|
1
|
Zeichner SB, Ambros T, Zaravinos J,
Montero AJ, Mahtani RL, Ahn ER, Mani A, Markward NJ and Vogel CL:
Defining the survival benchmark for breast cancer patients with
systemic relapse. Breast Cancer (Auckl). 9:9–17. 2015.PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taatjes DJ, Fenick DJ and Koch TH: Nuclear
targeting and nuclear retention of anthracycline-formaldehyde
conjugates implicates DNA covalent bonding in the cytotoxic
mechanism of anthracyclines. Chem Res Toxicol. 12:588–596. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carrick S, Parker S, Thornton CE, Ghersi
D, Simes J and Wilcken N: Single agent versus combination
chemotherapy for metastatic breast cancer. Cochrane Database Syst
Rev. CD003372:2009.
|
|
5
|
O'Brien ME, Wigler N, Inbar M, Rosso R,
Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP,
et al: Reduced cardiotoxicity and comparable efficacy in a phase
III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil)
versus conventional doxorubicin for first-line treatment of
metastatic breast cancer. Ann Oncol. 15:440–449. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Keller AM, Mennel RG, Georgoulias VA,
Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz
G, Henderson IC, et al: Randomized phase III trial of pegylated
liposomal doxorubicin versus vinorelbine or mitomycin C plus
vinblastine in women with taxane-refractory advanced breast cancer.
J Clin Oncol. 22:3893–3901. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Piccart-Gebhart MJ, Burzykowski T, Buyse
M, Sledge G, Carmichael J, Luck HJ, Mackey JR, Nabholtz JM,
Paridaens R, Biganzoli L, et al: Taxanes alone or in combination
with anthracyclines as first-line therapy of patients with
metastatic breast cancer. J Clin Oncol. 26:1980–1986. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Buzdar AU, Singletary SE, Theriault RL,
Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel
N, et al: Prospective evaluation of paclitaxel versus combination
chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide
as neoadjuvant therapy in patients with operable breast cancer. J
Clin Oncol. 17:3412–3417. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shapiro CL and Recht A: Side effects of
adjuvant treatment of breast cancer. N Engl J Med. 344:1997–2008.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Klostergaard J, Leroux ME, Auzenne E,
Khodadadian M, Spohn W, Wu JY and Donato NJ: Hyperthermia engages
the intrinsic apoptotic pathway by enhancing upstream caspase
activation to overcome apoptotic resistance in MCF-7 breast
adenocarcinoma cells. J Cell Biochem. 98:356–369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mohamed F, Marchettini P, Stuart OA, Urano
M and Sugarbaker PH: Thermal enhancement of new chemotherapeutic
agents at moderate hyperthermia. Ann Surg Oncol. 10:463–468. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Westermann AM, Grosen EA, Katschinski DM,
Jager D, Rietbroek R, Schink JC, Tiggelaar CL, Jager E, Zum Vorde
sive Vörding P, Neuman A, et al: A pilot study of whole body
hyperthermia and carboplatin in platinum-resistant ovarian cancer.
Eur J Cancer. 37:1111–1117. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ressel A, Weiss C and Feyerabend T: Tumor
oxygenation after radiotherapy, chemotherapy, and/or hyperthermia
predicts tumor free survival. Int J Radiat Oncol Biol Phys.
49:1119–1125. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burd R, Dziedzic TS, Xu Y, Caligiuri MA,
Subjeck JR and Repasky EA: Tumor cell apoptosis, lymphocyte
recruitment and tumor vascular changes are induced by low
temperature, long duration (fever-like) whole body hyperthermia. J
Cell Physiol. 177:137–147. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peer AJ, Grimm MJ, Zynda ER and Repasky
EA: Diverse immune mechanisms may contribute to the survival
benefit seen in cancer patients receiving hyperthermia. Immunol
Res. 46:137–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Issels RD, Schlemmer M and Lindner LH: The
role of hyperthermia in combined treatment in the management of
soft tissue sarcoma. Curr Oncol Rep. 8:305–309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jones EL, Oleson JR, Prosnitz LR, Samulski
TV, Vujaskovic Z, Yu D, Sanders LL and Dewhirst MW: Randomized
trial of hyperthermia and radiation for superficial tumors. J Clin
Oncol. 23:3079–3085. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Westermann AM, Jones EL, Schem BC, van der
Steen-Banasik EM, Koper P, Mella O, Uitterhoeve AL, de Wit R, van
der Velden J, Burger C, et al: First results of triple-modality
treatment combining radiotherapy, chemotherapy, and hyperthermia
for the treatment of patients with stage IIB III, and IVA cervical
carcinoma. Cancer. 104:763–770. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
El-Kareh AW and Secomb TW: A theoretical
model for intraperitoneal delivery of cisplatin and the effect of
hyperthermia on drug penetration distance. Neoplasia. 6:117–127.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Frey B, Weiss EM, Rubner Y, Wunderlich R,
Ott OJ, Sauer R, Fietkau R and Gaipl US: Old and new facts about
hyperthermia-induced modulations of the immune system. Int J
Hyperthermia. 28:528–542. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamada Y, Itoh Y, Aoki S, Nakamura K, Taki
T, Naruse K, Tobiume M, Zennami K, Katsuda R, Kato Y, et al:
Preliminary results of M-VAC chemotherapy combined with mild
hyperthermia, a new therapeutic strategy for advanced or metastatic
transitional cell carcinoma of the urothelium. Cancer Chemother
Pharmacol. 64:1079–1083. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yellin A, Simansky DA, Paley M and Refaely
Y: Hyperthermic pleural perfusion with cisplatin: Early clinical
experience. Cancer. 92:2197–2203. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mujoomdar AA and Sugarbaker DJ:
Hyperthermic chemoperfusion for the treatment of malignant pleural
mesothelioma. Semin Thorac Cardiovasc Surg. Winter. 20:298–304.
2008.
|
|
24
|
Murthy R, Honavar SG, Naik M and Reddy VA:
Thermochemotherapy in hereditary retinoblastoma. Br J Ophthalmol.
87:14322003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin Y, Ma X, Zhang S, Meng H, Xu M, Yang
X, Xu W and Tian J: A tantalum oxide-based core/shell nanoparticle
for triple-modality image-guided chemo-thermal synergetic therapy
of esophageal carcinoma. Cancer Lett. 397:61–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huilgol NG: A retrospective analysis of
patients with head and neck cancer treated with radiation,
hyperthermia, and cetuximab: A brief report of outcome. J Cancer
Res Ther. 12:1164–1166. 2016.PubMed/NCBI
|
|
27
|
Tao Y, Guo Y, Liu W, Zhang J, Li X, Shen
L, Ru Y, Xue Y, Zheng J, Liu X, et al: AKT inhibitor suppresses
hyperthermia-induced Ndrg2 phosphorylation in gastric cancer cells.
Braz J Med Biol Res. 46:394–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kong G, Braun RD and Dewhirst MW:
Characterization of the effect of hyperthermia on nanoparticle
extravasation from tumor vasculature. Cancer Res. 61:3027–3032.
2001.PubMed/NCBI
|
|
29
|
Xie X, Shao X, Gao F, Jin H, Zhou J, Du L,
Zhang Y, Ouyang W, Wang X, Zhao L, et al: Effect of hyperthermia on
invasion ability and TGF-beta1 expression of breast carcinoma MCF-7
cells. Oncol Rep. 25:1573–1579. 2011.PubMed/NCBI
|
|
30
|
Kanaya Y, Doihara H, Shiroma K, Ogasawara
Y and Date H: Effect of combined therapy with the antiestrogen
agent toremifene and local hyperthermia on breast cancer cells
implanted in nude mice. Surg Today. 38:911–920. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sawaji Y, Sato T, Takeuchi A, Hirata M and
Ito A: Anti-angiogenic action of hyperthermia by suppressing gene
expression and production of tumour-derived vascular endothelial
growth factor in vivo and in vitro. Br J Cancer. 86:1597–1603.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Saga T, Sakahara H, Nakamoto Y, Sato N,
Ishimori T, Mamede M, Kobayashi H, Masunaga S, Sasai K, Kuroki M
and Konishi J: Enhancement of the therapeutic outcome of
radio-immunotherapy by combination with whole-body mild
hyperthermia. Eur J Cancer. 37:1429–1434. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rong Y and Mack P: Apoptosis induced by
hyperthermia in Dunn osteosarcoma cell line in vitro. Int J
Hyperthermia. 16:19–27. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang YH, Haegerstrand A and Frostegard J:
Effects of in vitro hyperthermia on proliferative responses and
lymphocyte activity. Clin Exp Immunol. 103:61–66. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Deezagi A, Manteghi S, Khosravani P,
Vaseli-Hagh N and Soheili ZS: Induced apoptosis by mild
hyperthermia occurs via telomerase inhibition on the three human
myeloid leukemia cell lines: TF-1, K562, and HL-60. Leuk Lymphoma.
50:1519–1527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Canbay E, Ishibashi H, Sako S, Mizumoto A,
Hirano M, Ichinose M, Takao N and Yonemura Y: Preoperative
carcinoembryonic antigen level predicts prognosis in patients with
pseudomyxoma peritonei treated with cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy. World J Surg.
37:1271–1276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Robins HI and Longo W: Whole body
hyperthermia: Simple complexities. Intensive Care Med. 25:898–900.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang Z, Yan W, Ming J and Yu Y: Docetaxel
weekly regimen in conjunction with RF hyperthermia for pretreated
locally advanced non-small cell lung cancer: A preliminary study.
BMC Cancer. 7:1892007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hildebrandt B, Drager J, Kerner T, Deja M,
Loffel J, Stroszczynski C, Ahlers O, Felix R, Riess H and Wust P:
Whole-body hyperthermia in the scope of von Ardenne's systemic
cancer multistep therapy (sCMT) combined with chemotherapy in
patients with metastatic colorectal cancer: A phase I/II study. Int
J Hyperthermia. 20:317–333. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Takahashi I, Emi Y, Hasuda S, Kakeji Y,
Maehara Y and Sugimachi K: Clinical application of hyperthermia
combined with anticancer drugs for the treatment of solid tumors.
Surgery. 131:S78–S84. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wendtner C, Abdel-Rahman S, Baumert J,
Falk MH, Krych M, Santl M, Hiddemann W and Issels RD: Treatment of
primary, recurrent or inadequately resected high-risk soft-tissue
sarcomas (STS) of adults: Results of a phase II pilot study
(RHT-95) of neoadjuvant chemotherapy combined with regional
hyperthermia. Eur J Cancer. 37:1609–1616. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kappel M, Stadeager C, Tvede N, Galbo H
and Pedersen BK: Effects of in vivo hyperthermia on natural killer
cell activity, in vitro proliferative responses and blood
mononuclear cell subpopulations. Clin Exp Immunol. 84:175–180.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lv F, Yu Y, Zhang B, Liang D, Li ZM and
You W: Inhibitory effects of mild hyperthermia plus docetaxel
therapy on ER(+/-) breast cancer cells and action mechanisms. J
Huazhong Univ Sci Technolog Med Sci. 33:870–876. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Michalakis J, Georgatos SD, de Bree E,
Polioudaki H, Romanos J, Georgoulias V, Tsiftsis DD and
Theodoropoulos PA: Short-term exposure of cancer cells to
micromolar doses of paclitaxel, with or without hyperthermia,
induces long-term inhibition of cell proliferation and cell death
in vitro. Ann Surg Oncol. 14:1220–1228. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Michalakis J, Georgatos SD, Romanos J,
Koutala H, Georgoulias V, Tsiftsis D and Theodoropoulos PA:
Micromolar taxol, with or without hyperthermia, induces mitotic
catastrophe and cell necrosis in HeLa cells. Cancer Chemother
Pharmacol. 56:615–622. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Urano M, Kuroda M and Nishimura Y: For the
clinical application of thermochemotherapy given at mild
temperatures. Int J Hyperthermia. 15:79–107. 1999. View Article : Google Scholar : PubMed/NCBI
|
